CD20-directed antibody indicated for several cancers and other conditions.
Non Hodgkin Lymphoma
A record number of new oncology treatments launched in the US last year and spending on cancer drugs soared. Here are the top 6 cancer drug trends revealed in the report.
Drug targets the CD79b protein on B-cells.
FDA approved the first biosimilar to rituximab (Rituxan, Genentech) to treat non-Hodgkin lymphoma.